Guideline for diagnosis and treatment of primary liver cancer （2026 edition）

To further enhance the standardization of the diagnosis and treatment of primary liver cancer， ensure the safety and quality of medical care， and protect the health rights and interests of patients， the National Health Commission of the People’s Republic of China organized the revision of Guidelines for the diagnosis and treatment of primary liver cancer （2024 edition） and formulated the 2026 edition of Guidelines for the diagnosis and treatment of primary liver cancer. Based on the prevalence， diagnosis， and treatment of liver cancer in China， the 2026 edition integrates the latest evidence-based medical findings， especially the original studies led by Chinese scholars and published in top international journals， and makes systematic revisions and content expansions across multiple dimensions， including framework structure， epidemiological data， prevention and screening， diagnostic techniques， treatment strategies， and pathological assessment. The guidelines comprehensively standardize the entire clinical pathway for liver cancer， covering the aspects of prevention， screening， diagnosis， staging， and treatment， thereby providing authoritative technical guidance for the clinical practice of primary liver cancer in China.